CTLA4 and cancer: Among these strategies, immune checkpoint blockade (ICB), specifically targeting the programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) axis and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), stands as a cornerstone of contemporary cancer immunotherapy.